<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095926</url>
  </required_header>
  <id_info>
    <org_study_id>EPOC-MS-001</org_study_id>
    <secondary_id>2009-011454-17</secondary_id>
    <nct_id>NCT01095926</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Doxorubicin in Children With Cancer</brief_title>
  <acronym>Doxo</acronym>
  <official_title>Phase II Pharmacokinetic Study to Assess the Age-dependency in the Clearance of Doxorubicin in Paediatric Patients With Solid Tumours and Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the
      predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity
      .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Paediatric patients up to the age of 17 years will be included. Number and time points
           of PK sampling will depend on age and tumour type.

        -  PK samples will be collected from two doxorubicin administrations. Analyzing samples
           from two doxorubicin administrations will allow distinguishing between interindividual,
           intraindividual and residual variability.

        -  Doxorubicin and its major metabolite doxorubicinol will be measured in plasma using HPLC

        -  In addition, the natriuretic peptide BNP and the precursors NT-pro ANP and NT-proBNP as
           well as troponin T will be measured in plasma up to 28 days after doxorubicin
           administration to evaluate their use as clinical markers for cardiotoxicity.

        -  A data set of max 5 samples (3 +2 (in the 1st + 2nd Doxorubicin sampling periods)) will
           be collected in the younger children (&lt; 3 years) and a data set of max. 8 samples ( 5 +
           3) will be collected in the older children. Samples will be taken at predefined time
           points/ time intervals.

        -  An additional DNA sample will be taken and analyzed for genetic polymorphisms. The
           influence of genotype on pharmacokinetics and metabolism will be investigated by
           appropriate statistical methods, including population pharmacokinetic analyses. Genes to
           study would include MDR1 and SLC22A16, both involved in the transport of doxorubicin and
           AKR1A1 and CBR1, both involved in the reduction of doxorubicin to doxorubicinol.
           Selected genotypes will be incorporated as covariates into the population
           pharmacokinetic models developed. The potential impact of genetic variation will be
           evaluated in the context of other sources of variability such as age, weight, gender etc
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess age-dependency in pharmacokinetics of doxorubicin in paediatric patients with solid tumours and leukaemia</measure>
    <time_frame>24h</time_frame>
    <description>Measure doxorubicin and doxorubicinol concentration in blood plasma. Collect samples at two different doxorubicin infusions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess interindividual, intraindividual and residual variability of PK parameters in children</measure>
    <time_frame>24h</time_frame>
    <description>Measure doxorubicin and doxorubicinol concentration in blood plasma. Collect samples at two different doxorubicin infusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess relationship between PK parameters and patient characteristics</measure>
    <time_frame>24h</time_frame>
    <description>Measure doxorubicin and doxorubicinol concentration in blood plasma. Collect samples at two different doxorubicin infusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore in a preliminary fashion genetic polymorphisms that may influence doxorubicin clearance</measure>
    <time_frame>5 years</time_frame>
    <description>Obtain one whole blood sample per patient, if separate consent was given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the potential role of natriuretic peptides and troponin as indicators for subclinical cardiotoxicity</measure>
    <time_frame>1 month</time_frame>
    <description>Measure troponin T, troponin I, BNP, NT-proBNP, NT-proANP. Collect samples at two different doxorubicin infusions before and up to 1month after doxorubicin administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Wilms Tumor</condition>
  <condition>Neuroblastoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin</intervention_name>
    <description>blood sampling before, during and after doxorubicin administration</description>
    <arm_group_label>Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients ≤ 17 years of age

          -  plan to receive at least two cycles of doxorubicin

          -  must be enrolled in a national or European protocol for treatment of Wilms Tumours,
             Neuroblastoma, Soft tissue sarcoma, Ewing Sarcoma or Acute lymphoblastic leukaemia and
             must be treated with doxorubicin according to that protocol Or Patients &lt; 3 years
             enrolled or listed in any national or European study protocol for any paediatric
             malignancy. Treatment with doxorubicin has to be according to that protocol.

          -  Parents or legal representative(s) must provide written informed consent to
             participate in the trial according to national regulations. Patients that are able to
             understand should provide assent to participate in the trial.

          -  Life expectancy of at least 3 month

          -  Karnofsky performance status of ≥ 70%

          -  Additional blood withdrawal is acceptable for the patient. The decision is left to the
             investigator

        Exclusion Criteria:

          -  prior cardiac problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Boos, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Nicolas Andre, National Study Manager France</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustanve Roussy</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60690</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Maurizio D'Incalci, National Study Manager Italy</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Milano</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica di Roma</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Childrens Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Childrens Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Alan Boddy, National Study Manager UK</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary, Sir James Spence Institute of Child Health</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>cancer</keyword>
  <keyword>troponin</keyword>
  <keyword>natriuretic peptide</keyword>
  <keyword>cardiotoxicity</keyword>
  <keyword>anthracyclines</keyword>
  <keyword>Ewing</keyword>
  <keyword>ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Wilms Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

